Is early antiviral therapy for recurrent hepatitis C after liver transplantation superior to later treatment? the answer is no

Liver Transplantation

Volumn 17, Issue 5, 2011, Pages 488-491

  Roche, Bruno ^a,b,c   Samuel, Didier ^a,b,c  

^a HÔPITAL PAUL BROUSSE   (France)

^b INSERM   (France)

^c Universite Paris Sud   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ANEMIA; ANTIVIRAL THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FIBROSIS; GRAFT SURVIVAL; HEPATITIS C; HUMAN; LIVER TRANSPLANTATION; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; END STAGE LIVER DISEASE; FIBROSIS; GENOTYPE; HEPATITIS C; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; RECURRENCE; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 79955064257     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22297     Document Type: Editorial

References (15)

1. Terrault NA, Berenguer M,. Treating hepatitis C infection in liver transplant recipients. Liver Transpl 2006; 12: 1192-1204. (Pubitemid 44194586)
2. Davis GL, Nelson DR, Terrault N, Pruett TL, Schiano TD, Fletcher CV, et al. A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Cicavir) in liver transplant recipients. Liver Transpl 2005; 11: 941-949. (Pubitemid 41122452)
3. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, Terrault NA,. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118-124. (Pubitemid 40095135)
4. Mazzaferro V, Tagger A, Schiavo M, Regalia E, Pulvirenti A, Ribero ML, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33: 1355-1357. (Pubitemid 32237879)
5. Reddy R, Fried M, Dickson R, Martin P, Schiff E, Torres M, et al. Interferon alfa-2b and ribavirin vs. placebo as early treatment in patients transplanted for hepatitis C end-stage liver disease: results of a multicentric, randomized trial [abstract]. Gastroenterology 2002; 122: 199A.
6. Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, Kokudo N,. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78: 1308-1311. (Pubitemid 39507969)
7. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289-298. (Pubitemid 40165372)
8. Bzowej N, Nelson D, Terrault N, Everson G, Teng L, Prabhakar A, Charlton M,. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011;17:528-538.
9. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-687. (Pubitemid 34183974)
10. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-210. (Pubitemid 34700779)
11. Kuo A, Tan V, Lan B, Khalili M, Feng S, Roberts JP, Terrault N,. Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. Liver Transpl 2008; 14: 1491-1497.
12. Berenguer M,. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287.
13. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K,. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-1599. (Pubitemid 43945798)
14. Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008; 15: 699-709.
15. Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 1766-1777.